Trial Profile
Phase I/II Study of the Combination of Inotuzumab Ozogamicin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Ursodeoxycholic acid (Primary) ; Blinatumomab; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methotrexate; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Updated Results (As of June 2023, n=75 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (n=71)presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results (n=110) presented at the 28th Congress of the European Haematology Association